U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07056478) titled 'RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients' on June 19.
Brief Summary: The objective of this study is to conduct a pragmatic, randomized, double-blind, active-controlled trial to assess the efficacy of receptor activator of nuclear factor-kB ligand (RANKL) inhibition in the treatment of sarcopenia in hip fractures.
Study Start Date: Jan. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Sarcopenia in Elderly
Intervention:
DRUG: Denosumab (Prolia)
60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly
DRUG: Zoledronic acide (Aclasta)
5mg intravenou...